Retrospective Observational Registry of Patients With Atrial Fibrillation From Vigo´s Health Area
NCT ID: NCT04364516
Last Updated: 2020-04-28
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
15000 participants
OBSERVATIONAL
2018-11-26
2023-11-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Health-related Quality of Life in Patients on Anticoagulants
NCT03134911
Cardiovascular Registry of Atrial Fibrillation
NCT04456842
Atrial Fibrillation at the Viennese University Emergency Department
NCT03272620
Natural History of COVID-19-Related Atrial Fibrillation
NCT04830774
"De Novo" Atrial Fibrillation in Patients With Heart Failure: Incidence; Predictors and Relevance.
NCT04755010
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Anticoagulation
Study of prognostic impact according to oral anticoagulation therapy (Vitamin K Antagonists or Direct Oral Anticoagulants)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospital Álvaro Cunqueiro
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
EMAD ABU ASSI, PhD, MD
Role: STUDY_DIRECTOR
University Hospital Alvaro Cunqueiro, Vigo, Spain
SERGIO RAPOSEIRAS ROUBIN, PhD, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospital Alvaro Cunqueiro, Vigo, Spain
ANDRES IÑIGUEZ ROMO, PhD, MD
Role: STUDY_CHAIR
University Hospital Alvaro Cunqueiro, Vigo, Spain
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Cardiology, Hospital Álvaro Cunqueiro
Vigo, Pontevedra, Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Abu-Assi E, Lizancos Castro A, Cespon-Fernandez M, Gonzalez-Bermudez I, Raposeiras Roubin S. Relative performance evaluation of four bleeding risk scores in atrial fibrillation patients. What does the new DOAC score provide? Int J Cardiol. 2024 Jul 15;407:132018. doi: 10.1016/j.ijcard.2024.132018. Epub 2024 Apr 3.
Dominguez-Erquicia P, Raposeiras-Roubin S, Abu-Assi E, Bouzon-Iglesias P, Parada-Barcia JA, Lizancos-Castro A, Gonzalez-Garcia A, Noriega-Caro VA, Ledo-Pineiro A, Iglesias-Otero C, Gonzalez-Bermudez I, Iniguez-Romo A. Comparison of Outcomes in Patients With Atrial Fibrillation Under Oral Anticoagulation Therapy Analyzed by Body Weight (<60, 60 to 100, and >100 kg). Am J Cardiol. 2022 Dec 1;184:41-47. doi: 10.1016/j.amjcard.2022.07.028. Epub 2022 Sep 27.
Raposeiras-Roubin S, Abu-Assi E, Lizancos Castro A, Barreiro Pardal C, Melendo Viu M, Cespon Fernandez M, Blanco Prieto S, Rossello X, Ibanez B, Filgueiras-Rama D, Iniguez Romo A. Nutrition status, obesity and outcomes in patients with atrial fibrillation. Rev Esp Cardiol (Engl Ed). 2022 Oct;75(10):825-832. doi: 10.1016/j.rec.2022.01.006. Epub 2022 Mar 9. English, Spanish.
Cespon-Fernandez M, Raposeiras-Roubin S, Abu-Assi E, Melendo-Viu M, Garcia-Campo E, Iniguez-Romo A. Renin-Angiotensin System Inhibitors Prognostic Benefit in Older Patients with Atrial Fibrillation. J Am Med Dir Assoc. 2021 Oct;22(10):2190-2195. doi: 10.1016/j.jamda.2021.01.063. Epub 2021 Feb 16.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HAC-ACO-2018-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.